Loading…

Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model

The aim of this study was to quantify tumor cell proliferation and growth, analyze tumor blood vessel development, and determine the efficacy of antiangiogenic and angiostatic therapy in targeting mature vessels in retinal tumors of the LH(BETA)T(AG) mouse model for retinoblastoma. LH(BETA)T(AG) mou...

Full description

Saved in:
Bibliographic Details
Published in:Investigative ophthalmology & visual science 2007-06, Vol.48 (6), p.2476-2482
Main Authors: Jockovich, Maria-Elena, Bajenaru, M Livia, Piña, Yolanda, Suarez, Fernando, Feuer, William, Fini, M Elizabeth, Murray, Timothy G
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 2482
container_issue 6
container_start_page 2476
container_title Investigative ophthalmology & visual science
container_volume 48
creator Jockovich, Maria-Elena
Bajenaru, M Livia
Piña, Yolanda
Suarez, Fernando
Feuer, William
Fini, M Elizabeth
Murray, Timothy G
description The aim of this study was to quantify tumor cell proliferation and growth, analyze tumor blood vessel development, and determine the efficacy of antiangiogenic and angiostatic therapy in targeting mature vessels in retinal tumors of the LH(BETA)T(AG) mouse model for retinoblastoma. LH(BETA)T(AG) mouse retinas were analyzed at 4, 8, 12, and 16 weeks of age. Tumor burden was analyzed by histology; cell proliferation, vessel density, angiogenesis, and vessel maturation were detected by immunofluorescence. To assess the efficacy of mature vessel targeting, 16-week-old mice were treated with single subconjunctival injections of the selective vascular-targeting drug combretastatin A4 prodrug (CA4P) or anecortave acetate, and eyes were analyzed 1 day and 1 week after injection to determine microvessel density and the number of angiogenic and mature vessels. Increased cell proliferation and angiogenesis were detected in the retinal inner nuclear layer (INL) before morphologic neoplastic changes were evident. As tumor size increased, angiogenesis diminished concomitantly with the appearance of mature vessels. Treatment with CA4P and anecortave acetate resulted in significant reductions in total vessel density. However, neither drug reduced the amount of alpha-smooth muscle actin (SMA)-positive, mature vessels. Results of this study provide new insight into the relationship between tumor growth and blood vessel development in the LH(BETA)T(AG) mouse and establish the framework for defining the selective action of two vessel-targeting drugs against new blood vessels compared with mature blood vessels. These findings suggest a high potential value in targeting the process of angiogenesis in the treatment of children with retinoblastoma.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70529283</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70529283</sourcerecordid><originalsourceid>FETCH-LOGICAL-p543-c7e44ecaa0f7a252bf01fe5ce5fcf04c29db5cf1d00f267d8022ed7ab85eae543</originalsourceid><addsrcrecordid>eNo1kEFLwzAYhnNQ3Jz-BclJtkMhSZNlO84xN2EgSO_la_plRpqmNqmwf2_F7fK-l4eHl_eGTBmXy4xJJifkPsYvxgTngt2RCddKKK7zKWk-MLk2VA3EFDzQNPjQ0x-MERvqIQ09JBda6nwHJkWK1joD5kyDvVIJ-tOf5ERdS9Mn0uNh_rIrNotivtkvqA9DxDFrbB7IrYUm4uOlZ6R43RXbQ3Z8379tN8esUzLPjEYp0QAwq0EoUVnGLSqDyhrLpBHrulLG8poxK5a6XjEhsNZQrRQCjoYZef7Xdn34HjCm0rtosGmgxXFMqZkSa7HKR_DpAg6Vx7rseuehP5fXe_JfPOhhyg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70529283</pqid></control><display><type>article</type><title>Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model</title><source>PubMed (Medline)</source><creator>Jockovich, Maria-Elena ; Bajenaru, M Livia ; Piña, Yolanda ; Suarez, Fernando ; Feuer, William ; Fini, M Elizabeth ; Murray, Timothy G</creator><creatorcontrib>Jockovich, Maria-Elena ; Bajenaru, M Livia ; Piña, Yolanda ; Suarez, Fernando ; Feuer, William ; Fini, M Elizabeth ; Murray, Timothy G</creatorcontrib><description>The aim of this study was to quantify tumor cell proliferation and growth, analyze tumor blood vessel development, and determine the efficacy of antiangiogenic and angiostatic therapy in targeting mature vessels in retinal tumors of the LH(BETA)T(AG) mouse model for retinoblastoma. LH(BETA)T(AG) mouse retinas were analyzed at 4, 8, 12, and 16 weeks of age. Tumor burden was analyzed by histology; cell proliferation, vessel density, angiogenesis, and vessel maturation were detected by immunofluorescence. To assess the efficacy of mature vessel targeting, 16-week-old mice were treated with single subconjunctival injections of the selective vascular-targeting drug combretastatin A4 prodrug (CA4P) or anecortave acetate, and eyes were analyzed 1 day and 1 week after injection to determine microvessel density and the number of angiogenic and mature vessels. Increased cell proliferation and angiogenesis were detected in the retinal inner nuclear layer (INL) before morphologic neoplastic changes were evident. As tumor size increased, angiogenesis diminished concomitantly with the appearance of mature vessels. Treatment with CA4P and anecortave acetate resulted in significant reductions in total vessel density. However, neither drug reduced the amount of alpha-smooth muscle actin (SMA)-positive, mature vessels. Results of this study provide new insight into the relationship between tumor growth and blood vessel development in the LH(BETA)T(AG) mouse and establish the framework for defining the selective action of two vessel-targeting drugs against new blood vessels compared with mature blood vessels. These findings suggest a high potential value in targeting the process of angiogenesis in the treatment of children with retinoblastoma.</description><identifier>ISSN: 0146-0404</identifier><identifier>PMID: 17525173</identifier><language>eng</language><publisher>United States</publisher><subject>Actins - metabolism ; Angiogenesis Inhibitors - therapeutic use ; Animals ; Antineoplastic Agents, Phytogenic - therapeutic use ; Bibenzyls - therapeutic use ; Biomarkers, Tumor - metabolism ; Cell Proliferation ; Disease Models, Animal ; Endoglin ; Endothelium, Vascular - metabolism ; Intracellular Signaling Peptides and Proteins - metabolism ; Ki-67 Antigen - metabolism ; Mice ; Mice, Transgenic ; Microscopy, Fluorescence ; Neovascularization, Pathologic - drug therapy ; Neovascularization, Pathologic - metabolism ; Neovascularization, Pathologic - pathology ; Pericytes - metabolism ; Pregnadienediols - therapeutic use ; Retinal Neoplasms - blood supply ; Retinal Neoplasms - metabolism ; Retinal Neoplasms - pathology ; Retinoblastoma - blood supply ; Retinoblastoma - metabolism ; Retinoblastoma - pathology ; Stilbenes - therapeutic use</subject><ispartof>Investigative ophthalmology &amp; visual science, 2007-06, Vol.48 (6), p.2476-2482</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17525173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jockovich, Maria-Elena</creatorcontrib><creatorcontrib>Bajenaru, M Livia</creatorcontrib><creatorcontrib>Piña, Yolanda</creatorcontrib><creatorcontrib>Suarez, Fernando</creatorcontrib><creatorcontrib>Feuer, William</creatorcontrib><creatorcontrib>Fini, M Elizabeth</creatorcontrib><creatorcontrib>Murray, Timothy G</creatorcontrib><title>Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model</title><title>Investigative ophthalmology &amp; visual science</title><addtitle>Invest Ophthalmol Vis Sci</addtitle><description>The aim of this study was to quantify tumor cell proliferation and growth, analyze tumor blood vessel development, and determine the efficacy of antiangiogenic and angiostatic therapy in targeting mature vessels in retinal tumors of the LH(BETA)T(AG) mouse model for retinoblastoma. LH(BETA)T(AG) mouse retinas were analyzed at 4, 8, 12, and 16 weeks of age. Tumor burden was analyzed by histology; cell proliferation, vessel density, angiogenesis, and vessel maturation were detected by immunofluorescence. To assess the efficacy of mature vessel targeting, 16-week-old mice were treated with single subconjunctival injections of the selective vascular-targeting drug combretastatin A4 prodrug (CA4P) or anecortave acetate, and eyes were analyzed 1 day and 1 week after injection to determine microvessel density and the number of angiogenic and mature vessels. Increased cell proliferation and angiogenesis were detected in the retinal inner nuclear layer (INL) before morphologic neoplastic changes were evident. As tumor size increased, angiogenesis diminished concomitantly with the appearance of mature vessels. Treatment with CA4P and anecortave acetate resulted in significant reductions in total vessel density. However, neither drug reduced the amount of alpha-smooth muscle actin (SMA)-positive, mature vessels. Results of this study provide new insight into the relationship between tumor growth and blood vessel development in the LH(BETA)T(AG) mouse and establish the framework for defining the selective action of two vessel-targeting drugs against new blood vessels compared with mature blood vessels. These findings suggest a high potential value in targeting the process of angiogenesis in the treatment of children with retinoblastoma.</description><subject>Actins - metabolism</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Animals</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Bibenzyls - therapeutic use</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cell Proliferation</subject><subject>Disease Models, Animal</subject><subject>Endoglin</subject><subject>Endothelium, Vascular - metabolism</subject><subject>Intracellular Signaling Peptides and Proteins - metabolism</subject><subject>Ki-67 Antigen - metabolism</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Microscopy, Fluorescence</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Neovascularization, Pathologic - metabolism</subject><subject>Neovascularization, Pathologic - pathology</subject><subject>Pericytes - metabolism</subject><subject>Pregnadienediols - therapeutic use</subject><subject>Retinal Neoplasms - blood supply</subject><subject>Retinal Neoplasms - metabolism</subject><subject>Retinal Neoplasms - pathology</subject><subject>Retinoblastoma - blood supply</subject><subject>Retinoblastoma - metabolism</subject><subject>Retinoblastoma - pathology</subject><subject>Stilbenes - therapeutic use</subject><issn>0146-0404</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNo1kEFLwzAYhnNQ3Jz-BclJtkMhSZNlO84xN2EgSO_la_plRpqmNqmwf2_F7fK-l4eHl_eGTBmXy4xJJifkPsYvxgTngt2RCddKKK7zKWk-MLk2VA3EFDzQNPjQ0x-MERvqIQ09JBda6nwHJkWK1joD5kyDvVIJ-tOf5ERdS9Mn0uNh_rIrNotivtkvqA9DxDFrbB7IrYUm4uOlZ6R43RXbQ3Z8379tN8esUzLPjEYp0QAwq0EoUVnGLSqDyhrLpBHrulLG8poxK5a6XjEhsNZQrRQCjoYZef7Xdn34HjCm0rtosGmgxXFMqZkSa7HKR_DpAg6Vx7rseuehP5fXe_JfPOhhyg</recordid><startdate>200706</startdate><enddate>200706</enddate><creator>Jockovich, Maria-Elena</creator><creator>Bajenaru, M Livia</creator><creator>Piña, Yolanda</creator><creator>Suarez, Fernando</creator><creator>Feuer, William</creator><creator>Fini, M Elizabeth</creator><creator>Murray, Timothy G</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200706</creationdate><title>Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model</title><author>Jockovich, Maria-Elena ; Bajenaru, M Livia ; Piña, Yolanda ; Suarez, Fernando ; Feuer, William ; Fini, M Elizabeth ; Murray, Timothy G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p543-c7e44ecaa0f7a252bf01fe5ce5fcf04c29db5cf1d00f267d8022ed7ab85eae543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Actins - metabolism</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Animals</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Bibenzyls - therapeutic use</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cell Proliferation</topic><topic>Disease Models, Animal</topic><topic>Endoglin</topic><topic>Endothelium, Vascular - metabolism</topic><topic>Intracellular Signaling Peptides and Proteins - metabolism</topic><topic>Ki-67 Antigen - metabolism</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Microscopy, Fluorescence</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Neovascularization, Pathologic - metabolism</topic><topic>Neovascularization, Pathologic - pathology</topic><topic>Pericytes - metabolism</topic><topic>Pregnadienediols - therapeutic use</topic><topic>Retinal Neoplasms - blood supply</topic><topic>Retinal Neoplasms - metabolism</topic><topic>Retinal Neoplasms - pathology</topic><topic>Retinoblastoma - blood supply</topic><topic>Retinoblastoma - metabolism</topic><topic>Retinoblastoma - pathology</topic><topic>Stilbenes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jockovich, Maria-Elena</creatorcontrib><creatorcontrib>Bajenaru, M Livia</creatorcontrib><creatorcontrib>Piña, Yolanda</creatorcontrib><creatorcontrib>Suarez, Fernando</creatorcontrib><creatorcontrib>Feuer, William</creatorcontrib><creatorcontrib>Fini, M Elizabeth</creatorcontrib><creatorcontrib>Murray, Timothy G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Investigative ophthalmology &amp; visual science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jockovich, Maria-Elena</au><au>Bajenaru, M Livia</au><au>Piña, Yolanda</au><au>Suarez, Fernando</au><au>Feuer, William</au><au>Fini, M Elizabeth</au><au>Murray, Timothy G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model</atitle><jtitle>Investigative ophthalmology &amp; visual science</jtitle><addtitle>Invest Ophthalmol Vis Sci</addtitle><date>2007-06</date><risdate>2007</risdate><volume>48</volume><issue>6</issue><spage>2476</spage><epage>2482</epage><pages>2476-2482</pages><issn>0146-0404</issn><abstract>The aim of this study was to quantify tumor cell proliferation and growth, analyze tumor blood vessel development, and determine the efficacy of antiangiogenic and angiostatic therapy in targeting mature vessels in retinal tumors of the LH(BETA)T(AG) mouse model for retinoblastoma. LH(BETA)T(AG) mouse retinas were analyzed at 4, 8, 12, and 16 weeks of age. Tumor burden was analyzed by histology; cell proliferation, vessel density, angiogenesis, and vessel maturation were detected by immunofluorescence. To assess the efficacy of mature vessel targeting, 16-week-old mice were treated with single subconjunctival injections of the selective vascular-targeting drug combretastatin A4 prodrug (CA4P) or anecortave acetate, and eyes were analyzed 1 day and 1 week after injection to determine microvessel density and the number of angiogenic and mature vessels. Increased cell proliferation and angiogenesis were detected in the retinal inner nuclear layer (INL) before morphologic neoplastic changes were evident. As tumor size increased, angiogenesis diminished concomitantly with the appearance of mature vessels. Treatment with CA4P and anecortave acetate resulted in significant reductions in total vessel density. However, neither drug reduced the amount of alpha-smooth muscle actin (SMA)-positive, mature vessels. Results of this study provide new insight into the relationship between tumor growth and blood vessel development in the LH(BETA)T(AG) mouse and establish the framework for defining the selective action of two vessel-targeting drugs against new blood vessels compared with mature blood vessels. These findings suggest a high potential value in targeting the process of angiogenesis in the treatment of children with retinoblastoma.</abstract><cop>United States</cop><pmid>17525173</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0146-0404
ispartof Investigative ophthalmology & visual science, 2007-06, Vol.48 (6), p.2476-2482
issn 0146-0404
language eng
recordid cdi_proquest_miscellaneous_70529283
source PubMed (Medline)
subjects Actins - metabolism
Angiogenesis Inhibitors - therapeutic use
Animals
Antineoplastic Agents, Phytogenic - therapeutic use
Bibenzyls - therapeutic use
Biomarkers, Tumor - metabolism
Cell Proliferation
Disease Models, Animal
Endoglin
Endothelium, Vascular - metabolism
Intracellular Signaling Peptides and Proteins - metabolism
Ki-67 Antigen - metabolism
Mice
Mice, Transgenic
Microscopy, Fluorescence
Neovascularization, Pathologic - drug therapy
Neovascularization, Pathologic - metabolism
Neovascularization, Pathologic - pathology
Pericytes - metabolism
Pregnadienediols - therapeutic use
Retinal Neoplasms - blood supply
Retinal Neoplasms - metabolism
Retinal Neoplasms - pathology
Retinoblastoma - blood supply
Retinoblastoma - metabolism
Retinoblastoma - pathology
Stilbenes - therapeutic use
title Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A57%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retinoblastoma%20tumor%20vessel%20maturation%20impacts%20efficacy%20of%20vessel%20targeting%20in%20the%20LH(BETA)T(AG)%20mouse%20model&rft.jtitle=Investigative%20ophthalmology%20&%20visual%20science&rft.au=Jockovich,%20Maria-Elena&rft.date=2007-06&rft.volume=48&rft.issue=6&rft.spage=2476&rft.epage=2482&rft.pages=2476-2482&rft.issn=0146-0404&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70529283%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p543-c7e44ecaa0f7a252bf01fe5ce5fcf04c29db5cf1d00f267d8022ed7ab85eae543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70529283&rft_id=info:pmid/17525173&rfr_iscdi=true